51 In a study in esophagogastric cancer, 100 patients were randomized to treatment with a covered Wallstent, Ultraflex stent or Gianturco-Z stent. Again, all groups had good palliation from dysphagia but major complications were more frequent in the Gianturco-Z stent group.23 In another randomized study, covered Wallstents were compared with covered Ultraflex stents in 53 patients with lower esophageal

cancer. The stents were equally effective for palliation with similar rates for complications.52 Larger diameter stents reduce the risk of recurrent dysphagia caused by stent migration, tumor ingrowth or food obstruction but are associated with higher rates for complications.53 With uncovered stents, tumor ingrowth causing recurrent dysphagia occurs in check details 20–30% of patients.22 Tumor ingrowth can find more be minimized by the use of covered stents but the frequency of migration of the stent increases, sometimes up to 28%.22,54–56 Reflux after stent insertion appears to be minimized by the use of stents with antireflux valves.57 After stent insertion in the upper esophagus, patients may have the sensation of a foreign body for at least 1 week but the symptom settles with time.58 Foreign body sensations can also be minimized by the use of a specifically designed Wallstent or by the use of stents with

restricted expansion of the proximal flange.59,60 Covered stents should always be used for malignant fistulae

in the esophagus and for esophageal perforation. Most of the published experiences are in case reports or small comparative studies.45,61–69 After the insertion of stents, symptoms improve in approximately 90% of patients, a similar response rate to bypass surgery (gastroenterostomy). Furthermore, stents have been associated with lower procedure-related morbidity, mortality and cost.45,63 Stents also provide a better quality of life than gastrostomy tubes64,65 but reintervention rates medchemexpress (15–40%) are higher for stents than for gastrojejunostomy.66 In addition, symptoms fail to improve in some patients despite the apparent successful deployment of stents. This may be related to a functional gastric outlet obstruction caused by diffuse carcinomatosis or malignant infiltration of the celiac axis.62 In a systematic review that included 606 patients, stents were successfully deployed in 97% and symptoms improved in 89%. Most patients were able to eat at least soft foods and mean survival was 12 weeks.67 In a multicenter study, stents were inserted in 176 patients with obstructing cancers of the pancreas, stomach or gallbladder. The majority of patients (70%) had duodenal strictures and stents were successfully deployed in 98% of patients. On follow-up, 84% of patients were able to maintain an oral diet and median survival was 21 weeks.